MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Qure.ai, Global Healthcare AI Leader, Raises $65 Million in Series D Funding Led by Lightspeed and 360 ONE Asset

NextEdge Admin

25 Sep 2024

2 min 43 sec

Qure.ai, a global innovator in healthcare AI, has secured $65 million in a Series D funding round to accelerate its expansion into the US and other markets, enhance investment in AI model development, and explore acquisitions of med-tech companies. This round was led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital. Existing investors, including Novo Holdings, Health Quad, and TeamFund, also contributed.

Since its founding in 2016, Qure.ai has focused on making healthcare more accessible and equitable worldwide. Its AI-powered solutions are now deployed in over 90 countries, across more than 3,000 sites, helping with the identification and management of critical diseases such as tuberculosis (TB), lung cancer, and stroke. The company holds 18 FDA-cleared indications, and its products meet Class IIb certification under EU MDR regulations. Headquartered in Mumbai, Qure.ai operates regional offices in New York, London, and Dubai.

Prashant Warier, Co-founder and CEO of Qure.ai, highlighted the company’s impact on overcoming healthcare bottlenecks, such as imaging reporting delays and workforce shortages, not only in the US and Europe but also in developing countries. Qure.ai collaborates with top pharma and med-tech firms, including AstraZeneca, Medtronic, and Johnson & Johnson, to accelerate early diagnosis and treatment. Warier noted the new funding as a major step in Qure.ai’s journey toward reaching a billion patients globally.

Dev Khare, Partner at Lightspeed, praised Qure.ai's leadership in AI-driven diagnostics, stating that their solutions rival radiologists in accuracy. Tarun Sharma, Fund Manager at 360 ONE Asset, underscored Qure.ai's significant impact on early diagnosis and treatment, particularly in high-mortality diseases like lung cancer and TB, in low-resource, high-disease burden regions.